481 related articles for article (PubMed ID: 19896224)
21. Nuclear reprogramming and pluripotency of embryonic cells: Application to the isolation of embryonic stem cells in farm animals.
Renard JP; Maruotti J; Jouneau A; Vignon X
Theriogenology; 2007 Sep; 68 Suppl 1():S196-205. PubMed ID: 17610945
[TBL] [Abstract][Full Text] [Related]
22. Stem cells and nuclear reprogramming.
Saric T; Hescheler J
Minim Invasive Ther Allied Technol; 2008; 17(2):64-78. PubMed ID: 18465442
[TBL] [Abstract][Full Text] [Related]
23. Impacts of recent advances in cardiovascular regenerative medicine on clinical therapies and drug discovery.
Murata M; Tohyama S; Fukuda K
Pharmacol Ther; 2010 May; 126(2):109-18. PubMed ID: 20156482
[TBL] [Abstract][Full Text] [Related]
24. Faithful reprogramming to pluripotency in mammals - what does nuclear transfer teach us?
Maruotti J; Jouneau A; Renard JP
Int J Dev Biol; 2010; 54(11-12):1609-21. PubMed ID: 21404182
[TBL] [Abstract][Full Text] [Related]
25. Small molecules in stem cell self-renewal and differentiation.
Schugar RC; Robbins PD; Deasy BM
Gene Ther; 2008 Jan; 15(2):126-35. PubMed ID: 17989703
[TBL] [Abstract][Full Text] [Related]
26. The application of human embryonic stem cell technologies to drug discovery.
Sartipy P; Björquist P; Strehl R; Hyllner J
Drug Discov Today; 2007 Sep; 12(17-18):688-99. PubMed ID: 17826681
[TBL] [Abstract][Full Text] [Related]
27. The reprogramming language of pluripotency.
Welstead GG; Schorderet P; Boyer LA
Curr Opin Genet Dev; 2008 Apr; 18(2):123-9. PubMed ID: 18356040
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in cardiovascular regenerative medicine: the induced pluripotent stem cell era.
Yuasa S; Fukuda K
Expert Rev Cardiovasc Ther; 2008 Jul; 6(6):803-10. PubMed ID: 18570618
[TBL] [Abstract][Full Text] [Related]
29. Stem cell sources for regenerative medicine.
Riazi AM; Kwon SY; Stanford WL
Methods Mol Biol; 2009; 482():55-90. PubMed ID: 19089350
[TBL] [Abstract][Full Text] [Related]
30. Functional immobilization of signaling proteins enables control of stem cell fate.
Alberti K; Davey RE; Onishi K; George S; Salchert K; Seib FP; Bornhäuser M; Pompe T; Nagy A; Werner C; Zandstra PW
Nat Methods; 2008 Jul; 5(7):645-50. PubMed ID: 18552855
[TBL] [Abstract][Full Text] [Related]
31. Genome-wide reprogramming in hybrids of somatic cells and embryonic stem cells.
Ambrosi DJ; Tanasijevic B; Kaur A; Obergfell C; O'Neill RJ; Krueger W; Rasmussen TP
Stem Cells; 2007 May; 25(5):1104-13. PubMed ID: 17272499
[TBL] [Abstract][Full Text] [Related]
32. Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery.
Braam SR; Passier R; Mummery CL
Trends Pharmacol Sci; 2009 Oct; 30(10):536-45. PubMed ID: 19762090
[TBL] [Abstract][Full Text] [Related]
33. Concise review: non-cell autonomous reprogramming: a nucleic acid-free approach to induction of pluripotency.
Parameswaran S; Balasubramanian S; Rao MS; Ahmad I
Stem Cells; 2011 Jul; 29(7):1013-20. PubMed ID: 21544901
[TBL] [Abstract][Full Text] [Related]
34. Exploiting pluripotency for therapeutic gain.
Deng W
Panminerva Med; 2010 Jun; 52(2):167-73. PubMed ID: 20517198
[TBL] [Abstract][Full Text] [Related]
35. Reprogram or reboot: small molecule approaches for the production of induced pluripotent stem cells and direct cell reprogramming.
Jung DW; Kim WH; Williams DR
ACS Chem Biol; 2014 Jan; 9(1):80-95. PubMed ID: 24245936
[TBL] [Abstract][Full Text] [Related]
36. Genomic analysis of induced pluripotent stem (iPS) cells: routes to reprogramming.
Kanawaty A; Henderson J
Bioessays; 2009 Feb; 31(2):134-8. PubMed ID: 19204985
[TBL] [Abstract][Full Text] [Related]
37. Factors to consider in the use of stem cells for pharmaceutic drug development and for chemical safety assessment.
Trosko JE; Chang CC
Toxicology; 2010 Mar; 270(1):18-34. PubMed ID: 19948204
[TBL] [Abstract][Full Text] [Related]
38. Reprogramming cell fate to pluripotency: the decision-making signalling pathways.
Sanges D; Cosma MP
Int J Dev Biol; 2010; 54(11-12):1575-87. PubMed ID: 21305473
[TBL] [Abstract][Full Text] [Related]
39. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2.
Huangfu D; Osafune K; Maehr R; Guo W; Eijkelenboom A; Chen S; Muhlestein W; Melton DA
Nat Biotechnol; 2008 Nov; 26(11):1269-75. PubMed ID: 18849973
[TBL] [Abstract][Full Text] [Related]
40. Epigenetics in embryonic stem cells: regulation of pluripotency and differentiation.
Atkinson S; Armstrong L
Cell Tissue Res; 2008 Jan; 331(1):23-9. PubMed ID: 18004593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
